Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

1.4K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.4K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

1.1K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
1.1K
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

997
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
997
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.3K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.3K
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

921
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
921
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

898
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
898

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Content Validity of Measurement Instruments Used to Assess Patient Quality of Life (QoL) in Women with Stress Urinary Incontinence: A Systematic Review.

International urogynecology journal·2026
Same author

On the complementary role of perineal ultrasound in evaluating female pelvic organ prolapse.

Gynecology and pelvic medicine·2026
Same author

Population-level migration modeling of North America's birds through data integration with BirdFlow.

Movement ecology·2026
Same author

Applying randomized control trial criteria to an ECPR cohort.

Resuscitation plus·2026
Same author

Idiopathic vulvodynia - a psychosomatic disease? A cross-sectional single-center study.

BMC women's health·2026
Same author

[ECMO Treatment for CPR in Shaare Zedek Medical Center - A Seven Year Cohort].

Harefuah·2026
Same journal

Praxis·2026
Same journal

[What do Swiss doctors think about cardiovascular risk factors and guidelines?]

Praxis·2026
Same journal

[Laser interstitial thermotherapy (LITT): a minimally invasive neurosurgical treatment option for brain tumours and radiation necrosis].

Praxis·2026
Same journal

[Persistent back pain after lifting trauma. From the trivial to the rare case].

Praxis·2026
Same journal

[A patient with dizziness and gait instability - a diagnostic challenge].

Praxis·2026
Same journal

[Meningoencephalitis caused by listeria monocytogenes].

Praxis·2026
See all related articles

Related Experiment Video

Updated: Apr 5, 2026

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice
11:46

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice

Published on: April 27, 2014

18.5K

[Interstitial cystitis/bladder pain syndrome (IC/BPS)].

David A Scheiner1, Daniele Perucchini, Daniel Fink

  • 11 Klinik für Gynäkologie, Universitätsspital Zürich.

Praxis
|August 20, 2015
PubMed
Summary
This summary is machine-generated.

Interstitial cystitis/bladder pain syndrome (BPS) is a chronic pain condition lacking a cure. Treatment focuses on symptom relief through a stepwise approach, from self-care to last-resort therapies like cystectomy.

Keywords:
Bladder Pain SyndromeInterstitielle Zystitisbladder pain syndromecystite interstitielleinterstitial cystitissyndrome de la vessie douloureuse

More Related Videos

Treating Low Back Pain in Failed Back Surgery Patients with Multicolumn-lead Spinal Cord Stimulation
04:42

Treating Low Back Pain in Failed Back Surgery Patients with Multicolumn-lead Spinal Cord Stimulation

Published on: June 26, 2018

15.3K
Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats
07:12

Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats

Published on: January 21, 2020

8.5K

Related Experiment Videos

Last Updated: Apr 5, 2026

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice
11:46

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice

Published on: April 27, 2014

18.5K
Treating Low Back Pain in Failed Back Surgery Patients with Multicolumn-lead Spinal Cord Stimulation
04:42

Treating Low Back Pain in Failed Back Surgery Patients with Multicolumn-lead Spinal Cord Stimulation

Published on: June 26, 2018

15.3K
Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats
07:12

Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats

Published on: January 21, 2020

8.5K

Area of Science:

  • Urology
  • Pain Management
  • Gastroenterology

Context:

  • Interstitial cystitis/bladder pain syndrome (BPS) is a poorly understood chronic pain condition.
  • BPS is diagnosed clinically, with current treatments prioritizing symptom management over a cure.

Purpose:

  • To outline the stepwise treatment approach for Interstitial Cystitis/Bladder Pain Syndrome (BPS) based on AUA clinical practice guidelines.
  • To detail the progression of therapies from first-line self-care to sixth-line cystectomy.

Summary:

  • The AUA guidelines propose a six-line therapy approach for BPS.
  • Therapies range from self-care and behavioral modification (first-line) to physical therapy and oral medications (second-line).
  • Third-line options include cystoscopy, hydrodistension, Hunner lesion treatment, or intravesical DMSO; fourth-line is neuromodulation; fifth-line involves BoNT injections or cyclosporin A; and sixth-line is cystectomy.

Impact:

  • Provides a structured framework for clinicians managing BPS patients.
  • Highlights the progressive nature of BPS treatment, emphasizing symptom relief and escalating interventions.
  • Informs patients about the available treatment options and their sequence in managing chronic bladder pain.